Drugs / SV001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06267183 | Jan 2024 → Nov 2026 expected | idiopathic pulmonary fibrosis | Shanghai Synvida Biotechnology Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07121413 | Nov 2025 → Dec 2026 expected | idiopathic pulmonary fibrosis | Shanghai Synvida Biotechnology Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06267183 ↗ |